Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings (Post-Meeting Edition).
Vol 25, No 18S (June 20 Supplement), 2007: 1093
© 2007 American Society of Clinical Oncology

This Article Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Oksuzoglu, B. Articles by Zengin, N. Search for Related Content PubMed Articles by Oksuzoglu, B. Articles by Zengin, N.

Abstract

Capecitabine/cisplatin doublet in antracycline and taxane pre-treated patients with metastatic breast carcinoma

Ankara Numune Education and Research Hospital, Ankara, Turkey; Mersin University Faculty of Medicine, Mersin, Turkey; Hacettepe University Oncology Institute, Ankara, Turkey

1093

Background: Treating heavily pretreated metastatic breast cancer patients is challenging. To evaluate the activity and toxicity of the combination of capecitabine and cisplatin (CapCisp) in antracycline and taxane pretreated metastatic breast carcinoma (MBC) patients was the aim of our study. Methods: Thirty-three female MBC patients, 20 to 61 years of age (median; 41) were included in the study. Patients received Cap 2x1000 mg/m² on days 1–14, and Cisp 60 mg/m² on day 1, repeated every 3 weeks. In the case of disease control without intolerable toxicity, single agent Cap was continued. Results: Infiltrative ductal carcinoma was the most common histology (88%). In 23 patients with assigned histological grade, 13% had grade 1, 48% grade 2, and 39% grade 3 disease. Estrogen receptor (ER), Progesteron receptor (PR), and c-ErbB2 were positive in 39%, 63%, and 42%, respectively. All patients were pretreated with antracycline and taxane on an adjuvant or palliative basis before CapCisp chemotherapy. Altogether were given 154 courses of CapCisp chemotherapy (range; 1–8 courses per patient, median; 5 courses). Disease control rate was 82% (complete response, n: 1; partial response, n:16, stable disease, n: 10, progressive disease, n: 6). Eleven patients continued with single agent Cap (median; 4, range; 3–6 cycles). Grade 1 and 2 nausea/vomiting (66.7%) and fatigue (60.6%) were the most frequently observed side effects. Grade 3 neutropenia was observed in 4 patients (12.1%). Median follow-up was 9.5 months or until death. Median duration of response was 5.1 months (3.2–6.9, %95 CI). Median time to disease progression was 6.3 months (3.8–8.8, %95 CI). Fifteen patients died, and median survival was 11.5 months (6.9–16.1, 95% CI). Conclusion: CapCispl doublet has an encouraging antitumor activity with acceptable and manageable toxicity in antracycline and taxane pretreated metastatic breast carcinoma patients.

No significant financial relationships to disclose.

Abstract presentation from the 2007 ASCO Annual Meeting